Leptoprol (Leuprorelin)

Leuprorelin initially stimulates pituitary GnRH receptors, causing a brief rise in LH and FSH. Continued exposure then desensitizes the receptors, leading to a sustained drop in LH and FSH secretion. The consequent reduction in testosterone and estrogen production underlies its therapeutic effect in hormone‑sensitive diseases.

The specific dose and dosing interval of leuprorelin are determined by the prescribing clinician based on the patient’s condition, disease severity, and treatment goals. Dosage may vary between monthly, quarterly or longer‑acting formulations, and should follow the prescriber’s instructions.

Leuprorelin is contraindicated during pregnancy because it can interfere with fetal hormonal development. It is also not recommended for breastfeeding mothers, as it may be excreted in breast milk and affect the infant’s endocrine system. Women of child‑bearing potential should use effective contraception.

To order Leptoprol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Leuprorelin is one of several GnRH agonists, offering comparable efficacy in suppressing sex‑steroid production. Compared with GnRH antagonists, it may cause an initial hormone surge before suppression. Alternative treatments such as androgen‑deprivation drugs or aromatase inhibitors target downstream pathways, but leuprorelin provides a direct upstream approach.

Leptoprol should be stored at ambient temperature, protected from moisture and light, and kept in its original packaging until use. Do not freeze the product. Follow any specific handling instructions provided with the shipment, and discard any vial that appears discolored or compromised.

Leptoprol is administered by subcutaneous injection, typically performed by a healthcare professional. The injection site is usually the abdomen or thigh, and the volume depends on the prescribed dose. Patients should be instructed on proper aseptic technique and rotating injection sites to minimize local reactions.

Serious risks include significant bone loss leading to osteoporosis, cardiovascular events such as thrombosis or hypertension, severe allergic reactions (anaphylaxis), and rare pituitary apoplexy. Patients should be monitored regularly for these complications, and any concerning symptoms should prompt immediate medical evaluation.

Leptoprol should not be used by individuals who are pregnant, planning to become pregnant, or breastfeeding. It is also contraindicated in patients with known hypersensitivity to leuprorelin or any component of the formulation, and caution is advised in those with severe liver disease or uncontrolled cardiovascular conditions.